8-K
CNS Pharmaceuticals, Inc. Announces Voting Results from 2026 Annual Meeting of Stockholders
8-K
CNS Pharmaceuticals Announces Strategic Corporate Pivot and $22.5 Million Financing
8-K
CNS Pharmaceuticals Announces $22.5 Million Private Placement and Board of Directors Changes
8-K
CNS Pharmaceuticals Announces Strategic Pivot and New Executive Leadership
8-K
CNS Pharmaceuticals Appoints New Chief Medical Officer and Finalizes Separation Agreement with Former CMO
8-K
CNS Pharmaceuticals Announces Appointment of New CFO and Restructuring of Financial Leadership
